Elias Jabbour, MD

Elias Jabbour, MD, provides an overview of the significance of the FDA approval of ponatinib plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

In the first article of this series, Elias Jabbour, MD, gives an overview of myelodysplastic syndrome and discusses the evolving treatment landscape.

In the first installment of this series, Elias Jabbour, MD, provides an overview of myelodysplastic syndrome, discusses the current treatment landscape for lower-risk MDS, and offers insights on factors that influence treatment selection.

Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.